European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Orphan designation: hydroxocobalamin acetate Treatment of homocystinuria and/or methylmalonic acidaemia due to genetic defects of intracellular cobalamin processing, 25/03/2026 Positive

Submitted by Anonymous (not verified) on 22 April 2026 - 9:41

Orphan designation: hydroxocobalamin acetate Treatment of homocystinuria and/or methylmalonic acidaemia due to genetic defects of intracellular cobalamin processing, 25/03/2026 Positive

Human medicines European public assessment report (EPAR): Pyrukynd, mitapivat, Date of authorisation: 09/11/2022, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 21 April 2026 - 15:31

Human medicines European public assessment report (EPAR): Pyrukynd, mitapivat, Date of authorisation: 09/11/2022, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Verquvo, vericiguat, Date of authorisation: 16/07/2021, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 21 April 2026 - 15:24

Human medicines European public assessment report (EPAR): Verquvo, vericiguat, Date of authorisation: 16/07/2021, Revision: 2, Status: Authorised

Clinical Data Publication (CDP) - Questions and Answers (Q&As) on the European Medicines Agency policy on the publication of clinical data for medicinal products for human use (Policy 0070) work-share initiative with Health Canada (HC)

Submitted by Anonymous (not verified) on 21 April 2026 - 15:17

Clinical Data Publication (CDP) - Questions and Answers (Q&As) on the European Medicines Agency policy on the publication of clinical data for medicinal products for human use (Policy 0070) work-share initiative with Health Canada (HC)

Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 21 April 2026 - 15:16

Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Ezmekly, mirdametinib, Date of authorisation: 17/07/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 21 April 2026 - 14:58

Human medicines European public assessment report (EPAR): Ezmekly, mirdametinib, Date of authorisation: 17/07/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Arsenic trioxide medac, arsenic trioxide, Date of authorisation: 17/09/2020, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 21 April 2026 - 14:26

Human medicines European public assessment report (EPAR): Arsenic trioxide medac, arsenic trioxide, Date of authorisation: 17/09/2020, Revision: 3, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More